These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8803722)

  • 1. Effect of a new beta-blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy.
    Yoshikawa T; Handa S; Akaishi M; Mitamura H; Ogawa S
    Jpn Circ J; 1996 May; 60(5):285-92. PubMed ID: 8803722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for idiopathic dilated cardiomyopathy.
    Yoshikawa T; Handa S; Akaishi M; Mitamura H; Ogawa S
    Cardiology; 1995; 86(3):217-23. PubMed ID: 7614494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.
    Gilbert EM; Anderson JL; Deitchman D; Yanowitz FG; O'Connell JB; Renlund DG; Bartholomew M; Mealey PC; Larrabee P; Bristow MR
    Am J Med; 1990 Mar; 88(3):223-9. PubMed ID: 1968710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy.
    Fujimura M; Yasumura Y; Ishida Y; Nakatani S; Komamura K; Yamagishi M; Miyatake K
    J Card Fail; 2000 Mar; 6(1):3-10. PubMed ID: 10746813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
    Quaife RA; Gilbert EM; Christian PE; Datz FL; Mealey PC; Volkman K; Olsen SL; Bristow MR
    Am J Cardiol; 1996 Oct; 78(7):779-84. PubMed ID: 8857482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy.
    Hara Y; Hamada M; Ohtsuka T; Ogimoto A; Saeki H; Matsunaka T; Suzuki J; Shigematsu Y
    Heart Vessels; 2002 Dec; 17(2):53-6. PubMed ID: 12541094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
    Kawai K; Hata K; Takaoka H; Kawai H; Yokoyama M
    Am Heart J; 2001 Jun; 141(6):925-32. PubMed ID: 11376305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy.
    Clements IP; Miller WL
    Am Heart J; 2001 Feb; 141(2):259. PubMed ID: 11174349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic therapy with nipradilol, a beta-adrenergic blocker, attenuated left ventricular remodeling following myocardial infarction in rats.
    Sonoki H; Nakamura M; Takeshita A
    Jpn J Pharmacol; 1997 Jun; 74(2):171-8. PubMed ID: 9243325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy.
    Hirooka K; Yasumura Y; Ishida Y; Hanatani A; Nakatani S; Komamura K; Hori M; Yamagishi M; Miyatake K
    Jpn Circ J; 2001 Nov; 65(11):931-6. PubMed ID: 11716241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy.
    Wisenbaugh T; Katz I; Davis J; Essop R; Skoularigis J; Middlemost S; Röthlisberger C; Skudicky D; Sareli P
    J Am Coll Cardiol; 1993 Apr; 21(5):1094-100. PubMed ID: 8096228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy.
    Kurum T; Tatli E; Yuksel M
    Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy.
    Fan CM; Yang H; Li YS; Xu L; Dou KF; Zhao JL; Yuan XQ; Zhao YF; Shi RF; Du XQ; Lu NQ
    Chin Med Sci J; 2007 Dec; 22(4):224-7. PubMed ID: 18254186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
    Lowes BD; Gilbert EM; Abraham WT; Minobe WA; Larrabee P; Ferguson D; Wolfel EE; Lindenfeld J; Tsvetkova T; Robertson AD; Quaife RA; Bristow MR
    N Engl J Med; 2002 May; 346(18):1357-65. PubMed ID: 11986409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
    Di Lenarda A; Sabbadini G; Salvatore L; Sinagra G; Mestroni L; Pinamonti B; Gregori D; Ciani F; Muzzi A; Klugmann S; Camerini F
    J Am Coll Cardiol; 1999 Jun; 33(7):1926-34. PubMed ID: 10362195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of beta-blocker therapy on myocardial perfusion defects in thallium-201 scintigraphy in patients with dilated cardiomyopathy.
    Hara Y; Inoue K; Ogimoto A; Ohtsuka T; Shigematsu Y; Nakata S; Higaki J
    Cardiology; 2005; 104(1):16-21. PubMed ID: 15942178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between the improvement of cardiac function and the myocardial uptake of I-123 metaiodobenzylguanidine in patients with dilated cardiomyopathy treated by beta-blocker].
    Wakita T; Numata Y; Ogata Y; Harada E; Mizumasa Y
    J Cardiol; 1995 Sep; 26(3):177-83. PubMed ID: 7473048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure.
    Gabrielli O; Puyó AM; De Rosa A; Armando I; Barontini M; Levin G
    Auton Autacoid Pharmacol; 2002; 22(5-6):261-8. PubMed ID: 12866806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure.
    Yoshikawa T; Handa S; Anzai T; Nishimura H; Baba A; Akaishi M; Mitamura H; Ogawa S
    Am Heart J; 1996 Feb; 131(2):329-36. PubMed ID: 8579029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.